We recently showed that the JAK inhibitor ruxolitinib, which also has relative selectivity for JAK1 and JAK2 and is currently approved for myelofibrosis, reversed disease in three AA patients in an open-label clinical trial of oral drug in moderate-to-severe disease (Xing et al., 2014). This evidence concerns the gene JAK1 and myelofibrosis.